Author Correction: 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy
Status PubMed-not-MEDLINE Language English Country United States Media electronic
Document type Published Erratum
PubMed
34702803
PubMed Central
PMC8548337
DOI
10.1038/s41408-021-00565-6
PII: 10.1038/s41408-021-00565-6
Knihovny.cz E-resources
- Publication type
- Published Erratum MeSH
AbbVie Inc North Chicago IL USA
Almazov National Medical Research Center Saint Petersburg Russia
Centre Hospitalier Le Mans Le Mans France
Chinese Academy of Medical Sciences Tianjin China
CIBERONC Instituto Carlos 3 Madrid Spain
CIUSSS EMTL Installation Maisonneuve Rosemont Montreal QC Canada
Eastern Health and Monash University Melbourne VIC Australia
Evaggelismos General Hospital Athens Greece
George Papanicolaou General Hospital Thessalonica Greece
Heartlands Hospital Birmingham UK
Hospital Universitario y Politécnico La Fe Valencia Spain
Hubertus Wald University Cancer Center University Medical Center Hamburg Eppendorf Hamburg Germany
National and Kapodistrian University of Athens Medical School Laiko General Hospital Athens Greece
Netcare Pretoria East Hospital Moreletapark Pretoria South Africa
Norton Cancer Institute Louisville KY USA
Seoul National University Hospital Seoul South Korea
The Alfred Hospital and Monash University Melbourne VIC Australia
The University of Texas MD Anderson Cancer Center Houston TX USA
University of Fukui Hospital Fukui Japan
University of Pittsburgh Medical Center Cancer Center Pittsburgh PA USA
References provided by Crossref.org
